摘要
目的观察盐酸替罗非班对急性冠脉综合征(ACS)患者血清高敏C-反应蛋白(HS-CRP)水平的影响,了解盐酸替罗非班对ACS可能的炎症抑制机制。方法55例初诊为ACS的患者随机分为对照组(n=31)和试验组(n=24),试验组在对照组给予口服阿司匹林、氯吡格雷等常规治疗药物的基础上加用静脉滴注盐酸替罗非班,用超敏乳胶增强免疫比浊法测定ACS患者治疗前后hs-CRP水平。结果两组治疗前hs-CRP水平比较无明显差异(P>0.05);两组治疗后hs-CRP水平明显下降(P<0.01);治疗后两组hs-CRP水平比较差异有统计学意义(P<0.01)。结论盐酸替罗非班作为一种高效、高选择性的血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂,能够通过抑制炎性反应从而延缓ACS进程。
Objective To observe the effect of tirofiban hydrochlotide on serum hs-CRP level, and to approach the mechanism of inhibiting inflammation of it in acute coronary syndromes. Method 55 patients were randomly divided into two groups ： control group（ n = 31 ） and tirofiban group（ n = 24） ,they all were treated with tirofiban hydrochloride plus routine medicine, Serum hs-CRP levels were determinded by the latex enhanced immunoturbidimetric method. Results The level of hs-CRP had no significant difference between two groups before treatment （ P 〉 0. 05 ）, but after treatment（P 〈 0. 05 ）, serum hs-CRP was significantly decreased by tirofiban hydrochloride treatment compared to the control group（P 〈 0. 01 ）. Conclusion Tirofiban hydrochloride can delay the process of ACS through inhibiting inflammation.
出处
《中国临床保健杂志》
CAS
2009年第1期25-27,共3页
Chinese Journal of Clinical Healthcare
